FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
As of 16:49 UTC on 17 Oct 2026, Kalshi prices “FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)” at 76%. The market has no Kalshi-reported volume in the last 24 hours. pdata.world compares it with 24 related events on Kalshi, Manifold and Polymarket.
If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars. Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial. In the EPICS-III trial, it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.
